Elexacaftor
Trikafta, Kaftrio (elexacaftor) is a small molecule pharmaceutical. Elexacaftor was first approved as Trikafta on 2019-10-21. It is used to treat cystic fibrosis in the USA. It has been approved in Europe to treat cystic fibrosis. It is known to target cystic fibrosis transmembrane conductance regulator. Trikafta's patents are valid until 2037-12-08 (FDA).
| Trade Name | Kaftrio |
|---|---|
| Common Name | Elexacaftor |
| Indication | cystic fibrosis |
| Drug Class | Cystic fibrosis transmembrane regulator (CFTR) protein modulators |
